1,311 results on '"Paradis, Valérie"'
Search Results
152. Gut roundtable meeting paper: selected recent advances in hepatocellular carcinoma
153. Ultra‐short bowel is an independent risk factor for liver fibrosis in adults with home parenteral nutrition
154. Liver Stiffness by Transient Elastography to Detect Porto‐Sinusoidal Vascular Liver Disease With Portal Hypertension
155. Contributors
156. Tumors of the liver
157. Benign liver lesions
158. Cystic hepatobiliary neoplasia
159. Comparative Analysis of a Locally Resampling MR Elastography Reconstruction Algorithm in Liver Fibrosis.
160. High Prevalence of NASH and Advanced Fibrosis in Type 2 Diabetes: A Prospective Study of 330 Outpatients Undergoing Liver Biopsies for Elevated ALT, Using a Low Threshold.
161. Obesity-induced pancreatopathy in rats is reversible after bariatric surgery
162. Assessment of the residual tumour of colorectal liver metastases after chemotherapy: diffusion-weighted MR magnetic resonance imaging in the peripheral and entire tumour
163. When Should We Propose Liver Transplant After Resection of Hepatocellular Carcinoma? A Comparison of Salvage and De Principe Strategies
164. Primary Hepatic Malignant Neoplasms: Radiologic-Pathologic Correlations
165. Deleting the β-catenin degradation domain in mouse hepatocytes drives hepatocellular carcinoma or hepatoblastoma-like tumor growth
166. Molecular deciphering of primary liver neuroendocrine neoplasms confirms their distinct existence with foregut‐like profile
167. Functionnal and mitochondrial dynamics alterations in patients with chronic hepatitis B and advanced fibrosis
168. MAIT cell inhibition promotes liver fibrosis regression by reprogramming macrophage phenotype
169. Systemic treatments with tyrosine kinase inhibitors and platinum-based chemotherapy in patients with unresectable or metastatic hepato-cholangiocarcinoma
170. Replication stress triggered by nucleotide pool imbalance drives DNA damage and cGAS-STING pathway activation in NAFLD
171. Is there a murine model that fully recapitulates human NASH? An unbiased bioinformatics approach to rank pre-clinical models based on proximity to human disease
172. Arterial Calcifications in Patients with Liver Cirrhosis Are Linked to Hepatic Deficiency of Pyrophosphate Production Restored by Liver Transplantation
173. Hepatocellular Adenomas: WHO Classification and Immunohistochemical Workup
174. Pathologie hépatique Cirrhose et carcinome hépatocellulaire : indications et rôles de la biopsie hépatique
175. Systemic Treatments with Tyrosine Kinase Inhibitor and Platinum-Based Chemotherapy in Patients with Unresectable or Metastatic Hepatocholangiocarcinoma.
176. First-In-Human Effects of PPT1 Inhibition Using the Oral Treatment with GNS561/Ezurpimtrostat in Patients with Primary and Secondary Liver Cancers
177. Common genetic variation in alcohol-related hepatocellular carcinoma: a case-control genome-wide association study.
178. Mitochondrial stress in advanced fibrosis and cirrhosis associated with chronic hepatitis B, chronic hepatitis C, or nonalcoholic steatohepatitis.
179. Cytological Evaluation of Germinal Populations as Part of a Testicular Sperm Retrieval Strategy
180. Reply to: “Malignant transformation of hepatocellular adenoma”
181. Abnormal Plasma Microparticles Impair Vasoconstrictor Responses in Patients With Cirrhosis
182. Corrigendum to: ‘Telomere length is key to hepatocellular carcinoma diversity and telomerase addiction is an actionable therapeutic target’ [J Hepatol 2021 (74) 1155-1166]
183. Clinical Interest of Serum Alpha-2 Macroglobulin, Apolipoprotein A1, and Haptoglobin in Patients with Non-Alcoholic Fatty Liver Disease, with and without Type 2 Diabetes, before or during COVID-19
184. Sa1638 SAFETY AND EFFICACY OF REP 2139-MG AGAINST HBV / HDV COINFECTION WITH ADVANCED LIVER DISEASE
185. ZEB1 promotes cholangiocarcinoma progression through tumor dedifferentiation and tumor-stroma paracrine signaling
186. Changes in Autophagic Response in Patients with Chronic Hepatitis C Virus Infection
187. Contrast‐enhanced CT and liver surface nodularity for the diagnosis of porto‐sinusoidal vascular disorder: A case‐control study
188. Performance of non-invasive biomarkers compared with invasive methods for risk prediction of posthepatectomy liver failure in hepatocellular carcinoma
189. Gene expression signature as a surrogate marker of microvascular invasion on routine hepatocellular carcinoma biopsies
190. Immune Profiling of Combined Hepatocellular- Cholangiocarcinoma Reveals Distinct Subtypes and Activation of Gene Signatures Predictive of Response to Immunotherapy
191. Systemic Treatments with Tyrosine Kinase Inhibitor and Platinum-Based Chemotherapy in Patients with Unresectable or Metastatic Hepatocholangiocarcinoma
192. Reply to Letter to the Editor: Malignant transformation of hepatocellular adenoma
193. First-In-Human Effects of PPT1 Inhibition Using the Oral Treatment with GNS561/Ezurpimtrostat in Patients with Primary and Secondary Liver Cancers
194. Common genetic variation in alcohol-related hepatocellular carcinoma: a case-control genome-wide association study
195. Hepatic fibroblast growth factor 23 production in autosomal dominant polycystic kidney disease: YPO.015
196. Liver steatosis assessed by preoperative MRI: An independent risk factor for severe complications after major hepatic resection
197. Body weight changes and duration of estrogen exposure modulate the evolution of hepatocellular adenomas after contraception discontinuation.
198. List of Contributors
199. Histoséminaire de la société française de pathologie : biopsies et tumeurs hépatiques – Cas N° 1
200. Histoséminaire de la société française de pathologie : biopsies et tumeurs hépatiques – cas no°2 et no 3
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.